Global Sunitinib Malate Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Sunitinib Malate Market Research Report 2024
Sunitinib Malate is the orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.
According to Mr Accuracy reports new survey, global Sunitinib Malate market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029.
Key manufacturers engaged in the Sunitinib Malate industry include Pfizer Sutent, Topcare pharmaceutical Co., Ltd, Nanjing First Pharmaceutical Co., Ltd., J&K Scientific, Target Molecule Corp., CSPC, Qilu Pharmaceutical and Hansoh Pharma, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Sunitinib Malate were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Sunitinib Malate market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sunitinib Malate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer Sutent
Topcare pharmaceutical Co., Ltd
Nanjing First Pharmaceutical Co., Ltd.
J&K Scientific
Target Molecule Corp.
CSPC
Qilu Pharmaceutical
Hansoh Pharma
Segment by Type
12.5mg
37.5mg
50mg
Advanced Kidney Cancer
GIST (Gastrointestinal Stromal Tumor)
Pancreatic Neuroendocrine Tumors
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Sunitinib Malate report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Sunitinib Malate market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029.
Key manufacturers engaged in the Sunitinib Malate industry include Pfizer Sutent, Topcare pharmaceutical Co., Ltd, Nanjing First Pharmaceutical Co., Ltd., J&K Scientific, Target Molecule Corp., CSPC, Qilu Pharmaceutical and Hansoh Pharma, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Sunitinib Malate were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Sunitinib Malate market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sunitinib Malate market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer Sutent
Topcare pharmaceutical Co., Ltd
Nanjing First Pharmaceutical Co., Ltd.
J&K Scientific
Target Molecule Corp.
CSPC
Qilu Pharmaceutical
Hansoh Pharma
Segment by Type
12.5mg
37.5mg
50mg
Segment by Application
Advanced Kidney Cancer
GIST (Gastrointestinal Stromal Tumor)
Pancreatic Neuroendocrine Tumors
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Sunitinib Malate report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source